Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder (BOREAL)

Allergan

Status: Completed

Conditions: Urinary Bladder, Overactive; Urinary Bladder, Neurogenic

Treatments: Biological: botulinum toxin Type A

Study type: Observational

Funder types: Industry

Identifiers

NCT02673047

MAF/AGN/NS/OAB/006

Details and patient eligibility

About

This study will describe the prescription conditions of botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) or idiopathic overactive bladder (IOAB) as per standard of care in clinical practice in France.

Enrollment: 474 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-Patients who receive a Botox® injection for urinary incontinence.

Exclusion criteria

-Patients not residing in France.

Trial design

474 participants in 1 patient group

Botox®

Description:

Patients prescribed botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence associated with neurogenic detrusor overactivity or overactive bladder as per standard of care in clinical practice.

Treatment:

Biological: botulinum toxin Type A